These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 10553756

  • 1. Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder.
    Marazziti D, Pallanti S.
    Am J Psychiatry; 1999 Nov; 156(11):1834-5. PubMed ID: 10553756
    [No Abstract] [Full Text] [Related]

  • 2. Olanzapine-sertraline combination in schizophrenia with obsessive-compulsive disorder.
    Poyurovsky M, Kurs R, Weizman A.
    J Clin Psychiatry; 2003 May; 64(5):611. PubMed ID: 12755669
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Refractory obsessive-compulsive disorder: state-of-the-art treatment.
    Hollander E, Bienstock CA, Koran LM, Pallanti S, Marazziti D, Rasmussen SA, Ravizza L, Benkelfat C, Saxena S, Greenberg BD, Sasson Y, Zohar J.
    J Clin Psychiatry; 2002 May; 63 Suppl 6():20-9. PubMed ID: 12027116
    [Abstract] [Full Text] [Related]

  • 5. Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder.
    Potenza MN, Wasylink S, Longhurst JG, Epperson CN, McDougle CJ.
    J Clin Psychopharmacol; 1998 Oct; 18(5):423-4. PubMed ID: 9790164
    [No Abstract] [Full Text] [Related]

  • 6. Priapism associated with polypharmacy.
    Seger A, Lamberti JS.
    J Clin Psychiatry; 2001 Feb; 62(2):128. PubMed ID: 11247100
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms.
    Poyurovsky M, Dorfman-Etrog P, Hermesh H, Munitz H, Tollefson GD, Weizman A.
    Int Clin Psychopharmacol; 2000 May; 15(3):169-73. PubMed ID: 10870875
    [Abstract] [Full Text] [Related]

  • 9. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: an open study.
    Francobandiera G.
    Can J Psychiatry; 2001 May; 46(4):356-8. PubMed ID: 11387793
    [Abstract] [Full Text] [Related]

  • 10. Neuropsychiatric sequelae in a case of St. Louis encephalitis.
    Neel JL.
    Gen Hosp Psychiatry; 2000 May; 22(2):126-8. PubMed ID: 10896493
    [No Abstract] [Full Text] [Related]

  • 11. Olanzapine treatment of obsessive-compulsive disorder.
    Degner D, Bleich S, Kornhuber J, Rüther E.
    Can J Psychiatry; 2000 May; 45(4):393. PubMed ID: 10813075
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Hyperpigmentation with amisulpride.
    Mendhekar DN.
    Aust N Z J Psychiatry; 2009 Jan; 43(1):88. PubMed ID: 19086350
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Successful treatment of nondelusional body dysmorphic disorder with olanzapine: a case report.
    Grant JE.
    J Clin Psychiatry; 2001 Apr; 62(4):297-8. PubMed ID: 11379848
    [No Abstract] [Full Text] [Related]

  • 18. Olanzapine-induced obsessive-compulsive disorder.
    Mottard JP, de la Sablonnière JF.
    Am J Psychiatry; 1999 May; 156(5):799-800. PubMed ID: 10327925
    [No Abstract] [Full Text] [Related]

  • 19. Antidepressant augmentation with low-dose olanzapine in obsessive-compulsive disorder.
    Marusic A, Farmer A.
    Br J Psychiatry; 2000 Dec; 177():567. PubMed ID: 11270368
    [No Abstract] [Full Text] [Related]

  • 20. Obsessive-compulsive symptoms in schizophrenia: a comparison of olanzapine and placebo.
    Baker RW, Ames D, Umbricht DS, Chengappa KN, Schooler NR.
    Psychopharmacol Bull; 1996 Dec; 32(1):89-93. PubMed ID: 8927681
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.